The goal was to evaluate the activity of two novel heme targeting drugs in Non-Small Cell Lung Cancer models using multi-modality imaging. We found that the novel heme targeting drugs CycT (cyclopamine tartrate) and HSP2 (heme-sequestering peptide 2) were effective in suppressing NSCLC lung tumor growth as assessed by multimodality imaging and confirmed by pathology/histology. MRI detected the H1395 and H1299 orthotopic xenografts and was correlated with PET studies and histology.
This abstract and the presentation materials are available to members only; a login is required.